Joerg Rinnenthal
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules.
Journal: Molecular cancer therapeutics
Published: November 09, 2023
BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Journal: Neuro-oncology
Published: December 15, 2022
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo.
Journal: Nature communications
Published: March 02, 2022
Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist.
Journal: Molecular cancer therapeutics
Published: March 31, 2020
Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 13, 2020
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis.
Journal: Journal of medicinal chemistry
Published: August 01, 2019
Drugging an undruggable pocket on KRAS.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 24, 2019
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.
Journal: Nature chemical biology
Published: July 04, 2019
Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions.
Journal: Journal of medicinal chemistry
Published: February 12, 2019
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.
Journal: Nature chemical biology
Published: August 14, 2018
Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.
Journal: Journal of medicinal chemistry
Published: October 25, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026